

# Contents

## Part I Diagnostics

<b>1 Biopsy of Bone and Soft Tissue Tumours:</b>	
<b>Hints and Hazards.....</b>	<b>3</b>
Andreas Leithner, Werner Maurer-Ertl, and Reinhard Windhager	
1.1 Introduction .....	3
1.2 Diagnostic Algorithm .....	3
1.3 Biopsy.....	5
1.3.1 Biopsy Technique .....	6
1.4 Hints .....	7
1.5 Hazards.....	7
1.6 Definitive Diagnosis.....	9
References .....	10
<b>2 The Role of Intra-operative Pathological Evaluation</b>	
<b>in the Management of Musculoskeletal Tumours.....</b>	<b>11</b>
Robert U. Ashford, Richard A. Scolyer, Stanley W. McCarthy, S. Fiona Bonar, Rooshdiya Z. Karim, and Paul D. Stalley	
2.1 Introduction: Indications for Intra-operative Pathological Evaluation in Musculoskeletal Surgical Oncology.....	11
2.2 Pathological Options for Intra-operative Evaluation.....	12
2.2.1 Frozen Section.....	12
2.2.2 Fine Needle Aspiration Cytology .....	14
2.2.3 Touch Imprint Cytology .....	16
2.3 Uses of Frozen Section in Musculoskeletal Tumours.....	16
2.3.1 Operative Core Biopsy of Presumed Sarcoma .....	17
2.3.2 Surgical Margin Biopsy/Imprint.....	18
2.3.3 Confirmation of Diagnosis Prior to Definitive Treatment .....	19
2.3.4 Evaluation of Tumour Spread.....	20
2.3.5 Intramedullary Nailing of Presumed Metastasis .....	20

2.3.6	Frozen Section for Everyone? .....	20
2.3.7	Beware the Pitfalls of Frozen Section .....	20
2.4	Cost-Effectiveness .....	21
2.5	Discussion .....	22
	References .....	23
<b>3</b>	<b>Sentinel Node Biopsy in Soft Tissue Sarcoma</b> .....	<b>25</b>
	Dimosthenis Andreou and Per-Ulf Tunn	
3.1	Introduction .....	25
3.2	Technique of Lymphatic Mapping and Sentinel Lymph Node Biopsy .....	26
3.2.1	Preoperative Lymphoscintigraphy .....	26
3.2.2	Intraoperative Lymphatic Mapping .....	28
3.2.3	Histopathological Examination .....	30
3.3	Sentinel Node Biopsy in the Management of Soft Tissue Sarcoma .....	31
3.3.1	Clear Cell Sarcoma .....	31
3.3.2	Synovial Sarcoma .....	31
3.3.3	Rhabdomyosarcoma .....	32
3.3.4	Epithelioid Sarcoma .....	32
3.4	Discussion .....	33
	References .....	34
<b>Part II Bone Sarcomas</b>		
<b>4</b>	<b>Modular Endoprosthetic Reconstruction in Malignant Bone Tumors: Indications and Limits</b> .....	<b>39</b>
	Maurice Balke, Helmut Ahrens, Arne Streitbürger, Georg Gosheger, and Jendrik Hardes	
4.1	Introduction .....	39
4.2	Surgical Technique .....	40
4.3	Postoperative Management .....	42
4.4	Complications .....	42
4.5	Indications and Limits .....	44
4.5.1	Tumor Prostheses in Children .....	45
4.6	Functional Results .....	46
	Summary .....	47
	References .....	48

<b>5</b>	<b>Allograft Reconstruction in Malignant Bone Tumors:</b>	
	<b>Indications and Limits</b> .....	51
	Kevin A. Raskin and Francis Hornicek	
5.1	Introduction .....	51
5.1.1	Biology .....	52
5.2	Indications and Types .....	52
5.2.1	Intercalary Allografts.....	52
5.2.2	Osteoarticular Allografts .....	53
5.2.3	Allograft Arthrodesis.....	53
5.2.4	Allograft–Prosthetic Composites .....	55
5.3	Limits.....	55
	Summary .....	57
	References .....	57
<b>6</b>	<b>Expandable Endoprostheses in Malignant Bone Tumors in Children:</b>	
	<b>Indications and Limitations</b> .....	59
	Rainer Baumgart and Ulrich Lenze	
6.1	Introduction .....	59
6.2	Principles of Expandable Tumor Endoprosthesis .....	60
6.3	The Expandable Tumor Endoprosthesis MUTARS Xpand .....	61
6.4	The “Bioexpandable” Tumor Endoprosthesis MUTARS Bio-Xpand .....	62
6.5	Indications .....	64
6.5.1	Step 1 .....	64
6.5.2	Step 2.....	64
6.6	Limitations.....	65
6.7	Clinical Cases.....	66
6.8	Conclusion.....	68
	References .....	72
<b>7</b>	<b>The Long-Term Risks of Infection and Amputation</b>	
	<b>with Limb Salvage Surgery Using Endoprostheses</b> .....	75
	Lee Jeys and Robert Grimer	
7.1	Introduction .....	75
7.2	Long-Term Limb Salvage.....	76
7.3	Infection and Endoprostheses.....	77
7.4	New Techniques to Combat Infection.....	81
7.4.1	Surface Treatments .....	81
7.4.2	Antibiotic Prophylaxis.....	82
7.5	Conclusions .....	82
	References .....	82

<b>8</b>	<b>Reconstruction of the Pelvis After Resection of Malignant Bone Tumours in Children and Adolescents</b> .....	85
	Martin Dominkus, Eslam Darwish, and Philipp Funovics	
8.1	Introduction .....	85
8.2	Diagnosis .....	86
8.3	Biopsy.....	86
8.4	Preoperative Staging and Therapy.....	86
8.5	Resection Type I: Os Ilium .....	88
8.5.1	Partial Resection of the Ilium Without Discontinuity of the Pelvic Ring .....	88
8.5.2	Complete Resection of the Os Ilium with Discontinuity of the Pelvic Ring .....	88
8.6	Resection Type II: Acetabulum.....	89
8.6.1	Biological Reconstruction Methods .....	92
8.6.2	Endoprosthetic Reconstruction Methods .....	96
8.7	Resection Type I–II +/- IV .....	101
8.7.1	Allograft .....	101
8.7.2	Autograft .....	102
8.7.3	Flail Hip.....	102
8.7.4	Hip Transpositionplasty.....	102
8.8	Resection Type III.....	103
8.9	Resection Type II, III .....	104
8.10	Resection Type I–III/IV .....	104
8.10.1	Flail Hip: No Reconstruction .....	105
8.10.2	Hemipelvis Allograft .....	106
8.11	Future Aspects .....	108
	Summary .....	108
	References .....	109
<b>9</b>	<b>Methods of Biological Reconstruction for Bone Sarcoma: Indications and Limits</b> .....	113
	Pierre Kunz and Ludger Bernd	
9.1	Introduction .....	113
9.2	Biological Reconstruction Procedures and Outcome .....	114
9.2.1	Transplantation of Vital Autografts .....	114
9.2.2	Implantation of Avital Bone: Extracorporeal Devitalized Autografts.....	119
9.2.3	De Novo Bone Formation: Distraction Osteogenesis.....	123
9.3	Discussion .....	127
9.3.1	Vital Bone Grafts: Vascularization .....	128
9.3.2	Biomechanical Aspects in Free Bone Grafts: Union, Hypertrophy, Fracture.....	130
9.3.3	Complications and Functional Outcome in Vital Grafts .....	131
9.3.4	Extracorporeal Devitalized Grafts.....	131

9.3.5	Distraction Osteogenesis .....	132
9.3.6	Indications and Limitations .....	133
9.4	Conclusion.....	134
	References .....	135
<b>10</b>	<b>Bone Sarcoma of the Spine .....</b>	<b>141</b>
	Klaus-Dieter Schaser, I. Melcher, A. Luzzati, and A. C. Disch	
10.1	Introduction and Epidemiology .....	141
10.2	Clinical Presentation.....	142
10.3	Diagnostics and Radiographic Imaging .....	143
10.4	Role and Technique of Biopsy.....	143
10.5	Oncosurgical Staging Systems of Primary Vertebral Tumors .....	144
10.6	Surgical Approaches.....	146
10.6.1	Posterior/Posterolateral Approach .....	146
10.6.2	Anterior Approaches.....	146
10.7	Surgical Strategies, Patient Selection, Treatment Decisions and Surgical Techniques .....	149
10.8	Surgical Technique of En Bloc Spondylectomy/Total En Bloc Vertebrectomy.....	150
10.8.1	Resection Technique .....	151
10.8.2	Technique: Spinal Reconstruction.....	152
10.9	Current Management of Individual Primary Malignant Vertebral Column Tumors .....	152
10.9.1	Osteosarcoma .....	152
10.9.2	Ewing Sarcoma.....	155
10.9.3	Chondrosarcoma.....	158
10.9.4	Chordoma .....	158
10.10	Nonsurgical Treatment Options.....	159
10.10.1	Radiation .....	159
10.10.2	Chemotherapy.....	161
10.10.3	Embolization .....	161
10.10.4	Pain Management .....	161
10.11	Complications.....	161
10.12	Prognosis .....	162
	References .....	162
<b>11</b>	<b>Computer-Assisted Pelvic Tumor Resection: Fields of Application, Limits, and Perspectives.....</b>	<b>169</b>
	Sebastian Fehlberg, Sebastian Eulenstein, Thomas Lange, Dimosthenis Andreou, and Per-Ulf Tunn	
11.1	Introduction .....	169
11.2	Navigation Procedures.....	171
11.2.1	Preoperative Imaging and Segmentation.....	171

11.2.2	Tracking Systems .....	172
11.2.3	Intraoperative Patient-to-Image Registration .....	173
11.2.4	Intraoperative Visualization.....	176
11.3	Fields of Application .....	176
11.4	Clinical Results.....	178
11.5	Limits and Perspectives .....	179
	Summary .....	180
	References .....	180
<b>12</b>	<b>Pulmonary Metastasectomy for Osteosarcoma: Is It Justified?</b> .....	<b>183</b>
	Klaus-Dieter Diemel, Heinz-Jürgen Klippe, and Detlev Branscheid	
12.1	History of Osteosarcoma and Pulmonary Metastasectomy.....	183
12.2	Thoracic Surgery Becomes Important Part of Interdisciplinary Concepts .....	185
12.2.1	From Single-Centre Experience to Large Databases.....	187
12.3	Evaluating the Patient with Pulmonary Metastases.....	187
12.3.1	Computed Tomography of the Lung.....	188
12.3.2	SPECT and PET Scans.....	188
12.4	Prognostic Factors and Their Impact for Pulmonary Metastasectomy .....	189
12.4.1	Factors Correlating to Modalities and Therapies of the Primary Tumour .....	189
12.4.2	Factors Concerning the Time of Presentation of Metastases.....	190
12.4.3	Factors Concerning Properties of Metastases and Surgical Remission .....	190
12.5	Techniques in Pulmonary Metastasectomy .....	190
12.5.1	Operative Approach to the Metastatic Lung.....	190
12.5.2	Techniques in Pulmonary Resection .....	193
12.6	Our Own Results .....	196
12.7	Discussion .....	200
12.7.1	The Reviewed Studies .....	200
12.7.2	Risk Factors Affecting Survival After Pulmonary Metastasectomy .....	202
12.7.3	Surgical Approach for Pulmonary Metastasectomy .....	203
12.7.4	A Place for Minimally Invasive Surgery (VATS)? .....	204
12.8	Conclusions .....	204
	References .....	205

### Part III Soft Tissue Sarcomas

<b>13</b>	<b>Standardized Approach to the Treatment of Adult Soft Tissue Sarcoma of the Extremities</b> .....	211
	Per-Ulf Tunn, Christoph Kettelhack, and Hans Roland Dürr	
	Abbreviations .....	211
13.1	Introduction .....	212
13.2	Biopsy Techniques .....	212
13.3	Surgical Therapy in Soft Tissue Sarcoma: General Principles .....	213
13.3.1	The Influence of Surgical Margins .....	215
13.3.2	The Influence of an Unplanned Excision .....	216
13.3.3	The Influence of Local Recurrence .....	218
13.4	Neoadjuvant and Adjuvant Treatment Modalities in Soft Tissue Sarcoma .....	218
13.4.1	The Role of Systemic Chemotherapy .....	219
13.4.2	The Role of Isolated Limb Perfusion .....	220
13.4.3	The Role of Radiotherapy .....	220
13.4.4	Response Assessment After Neoadjuvant Treatment in Soft Tissue Sarcoma .....	222
	Summary .....	224
	References .....	224
<b>14</b>	<b>Evaluating Surgery Quality in Soft Tissue Sarcoma</b> .....	229
	Eberhard Stoeckle, Jean-Michel Coindre, Michèle Kind, Guy Kantor, and Binh N. Bui	
14.1	Introduction .....	229
14.2	What End-Points for Assessing Local Tumour Control? .....	230
14.3	Local Recurrence Rates .....	231
14.4	Margins and Their Impact on Local Control .....	232
14.4.1	Margin Determination and Local Outcome .....	232
14.4.2	Co-factors Influencing Margin Quality .....	235
14.4.3	Impact of Margin and Other Factors on Local Recurrence .....	237
14.5	Long-Term Follow-Up with Actuarial Estimates in Homogeneous Patient Groups .....	238
14.6	Recapitulation: Criteria for Evaluating Surgery Quality with STS .....	238
	References .....	238
<b>15</b>	<b>Peripheral Nerve Considerations in the Management of Extremity Soft Tissue Sarcomas</b> .....	243
	Peter C. Ferguson, Anna A. Kulidjian, Kevin B. Jones, Benjamin M. Deheshi, and Jay S. Wunder	
15.1	Introduction .....	243
15.2	Diagnosis of Peripheral Nerve Involvement .....	244

15.2.1	History and Physical Examination .....	244
15.2.2	Imaging.....	245
15.2.3	Other Diagnostic Considerations.....	246
15.3	Management of Peripheral Nerve Involvement.....	246
15.3.1	General Approach.....	246
15.3.2	Epineural Dissection.....	246
15.3.3	Nerve Resection Without Reconstruction .....	249
15.3.4	Nerve Resection and Reconstruction .....	252
15.3.5	Distal Functional Restoration: Tendon Transfers .....	253
15.3.6	Distal Functional Restoration: Distal Nerve Transfers.....	254
15.3.7	Amputation .....	254
15.4	Conclusions .....	255
	References .....	255
<b>16</b>	<b>Isolated Limb Perfusion with TNF-<math>\alpha</math> and Melphalan in Locally Advanced Soft Tissue Sarcomas of the Extremities .....</b>	<b>257</b>
	Dirk J. Grünhagen, Johannes H.W. de Wilt, Albertus N. Van Geel, Cornelis Verhoef, and Alexander M.M. Eggermont	
16.1	Introduction .....	257
16.2	Isolated Limb Perfusion .....	258
16.3	The Rationale for Using Tumour Necrosis Factor- $\alpha$ in ILP .....	259
16.4	TNF-Based Isolated Limb Perfusion for STS .....	261
16.5	Results with TNFPlus Doxorubicin.....	262
16.6	Toxicity of a TNF-Based ILP .....	262
16.7	Special Patient Categories .....	265
16.7.1	Patients with Overt Metastatic Disease .....	265
16.7.2	Patients with Multiple Tumours in the Extremity.....	265
16.7.3	Patients with Recurrent Tumours in an Irradiated Field.....	265
16.7.4	Elderly Patients (>75 Years Old) .....	265
16.7.5	TNF-Based ILP Activity in Other Histologies .....	265
16.8	Future Perspectives.....	266
16.9	Conclusions .....	266
	References .....	266
<b>17</b>	<b>Management of Locally Recurrent Soft Tissue Sarcoma after Prior Surgery and Radiation Therapy .....</b>	<b>271</b>
	Peter Hohenberger and Matthias H.M. Schwarzbach	
17.1	Introduction .....	271
17.2	Treatment Options .....	272
17.3	Problems for Surgery Encountered with Previous Radiotherapy .....	273
17.4	Practical Management of In-Field Sarcoma Recurrence.....	275
17.5	Treatment Decisions in Surgical Re-intervention .....	276
17.6	Indication for Multimodal Re-treatment .....	277
17.7	Conclusion.....	281
	References .....	281



<b>18</b>	<b>Management of Vascular Involvement in Extremity Soft Tissue Sarcoma</b> .....	285
	Ashish Mahendra, Yair Gortzak, Peter C. Ferguson, Benjamin M. Deheshi, Thomas F. Lindsay, and Jay S. Wunder	
18.1	Introduction .....	285
18.2	Indications for Vascular Resection and Reconstruction in Extremity Soft Tissue Sarcoma .....	286
18.3	Patient Workup .....	287
18.4	Surgical and Functional Outcome .....	289
18.4.1	Amputation Risk.....	290
18.4.2	Use of Muscle Flaps .....	290
18.4.3	Wound Complications .....	290
18.4.4	Postoperative Limb Edema and DVT .....	290
18.4.5	Risk of Local Recurrence .....	291
18.4.6	Risk of Systemic Disease .....	291
18.4.7	Functional Outcome .....	291
18.5	Vascular Outcome.....	293
18.5.1	Arterial Reconstruction .....	293
18.5.2	Venous Reconstruction .....	293
18.5.3	Type of Vascular Graft.....	294
18.6	Effects of Radiotherapy .....	296
	Summary .....	298
	References .....	298
<b>19</b>	<b>Current Concepts in the Management of Retroperitoneal Soft Tissue Sarcoma</b> .....	301
	Matthias H.M. Schwarzbach and Peter Hohenberger	
19.1	Introduction .....	301
19.2	Definitions Referring to Retroperitoneal Sarcomas.....	302
19.3	Diagnostic Requirements in Retroperitoneal Sarcomas.....	302
19.4	Vascular Involvement .....	303
19.5	Surgical Therapy in Localized Soft Tissue Sarcomas of the Retroperitoneum.....	305
19.6	Surgical Therapy in Metastasized Soft Tissue Sarcomas of the Retroperitoneum.....	314
19.7	Prognosis .....	315
19.8	Chemotherapy and Radiation Therapy .....	315
	Summary .....	317
	References .....	317

<b>20</b>	<b>Pulmonary Metastasectomy for Soft Tissue Sarcomas: Is It Justified?</b> .....	321
	Joachim Pfannschmidt, Hans Hoffmann, Thomas Schneider, and Hendrik Dienemann	
20.1	Introduction .....	321
20.2	Clinical Features .....	323
20.3	Radiology .....	323
20.4	Patient Selection .....	324
20.5	Surgery .....	325
20.6	Video-Assisted Thoracic Surgery .....	326
20.7	Prognostic Factors .....	327
20.7.1	Overall Survival .....	327
20.7.2	Recurrent Pulmonary Metastases .....	331
20.7.3	Perioperative Chemotherapy .....	331
20.8	Future Directions .....	332
20.9	Conclusions .....	333
	References .....	333
<b>Part IV Quality of Life Assessment</b>		
<b>21</b>	<b>Quality of Life (QOL) in Patients with Osteosarcoma</b> .....	339
	Rajaram Nagarajan	
21.1	Osteosarcoma .....	339
21.2	Treatment and Survival .....	340
21.3	Quality of Life .....	340
21.4	Outcomes Model .....	341
	References .....	343
<b>22</b>	<b>Clinical Trials in Osteosarcoma Treatment: Patients' Perspective Through Art</b> .....	345
	Lizzie Burns and Martha Perisoglou	
22.1	Introduction .....	345
22.2	Patients with Osteosarcoma and the EURAMOS 1 Clinical Trial .....	346
22.3	Bringing Medicine to Life .....	346
22.4	The Patients' Perspective .....	347
22.4.1	Syed .....	347
22.4.2	Omar .....	350
22.4.3	Shane .....	350
22.4.4	Laura .....	351
22.4.5	Meg .....	352
22.4.6	Simon .....	353

---

22.4.7	Bhavin.....	355
22.4.8	Sam.....	357
22.4.9	Charlie .....	357
22.5	Art and Cancer .....	359
22.6	Conclusion.....	360
	Acknowledgements .....	360
	References .....	360



<http://www.springer.com/978-3-540-77959-9>

Treatment of Bone and Soft Tissue Sarcomas

Tunn, P.-U. (Ed.)

2009, XXII, 362 p. 166 illus., 130 illus. in color.,

Hardcover

ISBN: 978-3-540-77959-9